- Home
- KRRO vs PLRX Comparison
KRRO vs PLRX Comparison
Compare KRRO & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRRO
- PLRX
- Stock Information
- Founded
- KRRO 2014
- PLRX 2015
- Country
- KRRO United States
- PLRX United States
- Employees
- KRRO N/A
- PLRX N/A
- Industry
- KRRO Biotechnology: Pharmaceutical Preparations
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- KRRO Health Care
- PLRX Health Care
- Exchange
- KRRO Nasdaq
- PLRX Nasdaq
- Market Cap
- KRRO 101.4M
- PLRX 84.7M
- IPO Year
- KRRO 2019
- PLRX 2020
- Fundamental
- Price
- KRRO $12.35
- PLRX $1.28
- Analyst Decision
- KRRO Strong Buy
- PLRX Hold
- Analyst Count
- KRRO 7
- PLRX 10
- Target Price
- KRRO $85.67
- PLRX $9.79
- AVG Volume (30 Days)
- KRRO 203.4K
- PLRX 950.8K
- Earning Date
- KRRO 08-12-2025
- PLRX 08-06-2025
- Dividend Yield
- KRRO N/A
- PLRX N/A
- EPS Growth
- KRRO N/A
- PLRX N/A
- EPS
- KRRO N/A
- PLRX N/A
- Revenue
- KRRO $4,821,000.00
- PLRX N/A
- Revenue This Year
- KRRO $65.08
- PLRX N/A
- Revenue Next Year
- KRRO N/A
- PLRX N/A
- P/E Ratio
- KRRO N/A
- PLRX N/A
- Revenue Growth
- KRRO N/A
- PLRX N/A
- 52 Week Low
- KRRO $10.29
- PLRX $1.10
- 52 Week High
- KRRO $98.00
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- KRRO 41.55
- PLRX 36.66
- Support Level
- KRRO $11.50
- PLRX $1.56
- Resistance Level
- KRRO $16.86
- PLRX $1.70
- Average True Range (ATR)
- KRRO 1.50
- PLRX 0.12
- MACD
- KRRO 0.01
- PLRX -0.02
- Stochastic Oscillator
- KRRO 31.35
- PLRX 5.68
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.